Preclinical multimodality phantom design for quality assurance of tumor size measurement

Yongsook C. Lee, Gary D. Fullerton, Cristel Baiu, Margaret G. Lescrenier, Beth A. Goins

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Evaluation of changes in tumor size from images acquired by ultrasound (US), computed tomography (CT) or magnetic resonance imaging (MRI) is a common measure of cancer chemotherapy efficacy. Tumor size measurement based on either the World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST) is the only imaging biomarker for anti-cancer drug testing presently approved by the United States Food and Drug Administration (FDA). The aim of this paper was to design and test a quality assurance phantom with the capability of monitoring tumor size changes with multiple preclinical imaging scanners (US, CT and MRI) in order to facilitate preclinical anti-cancer drug testing.Methods: Three phantoms (Gammex/UTHSCSA Mark 1, Gammex/UTHSCSA Mark 2 and UTHSCSA multimodality tumor measurement phantom) containing tumor-simulating test objects were designed and constructed. All three phantoms were scanned in US, CT and MRI devices. The size of test objects in the phantoms was measured from the US, CT and MRI images. RECIST, WHO and volume analyses were performed.Results: The smaller phantom size, simplified design and better test object CT contrast of the UTHSCSA multimodality tumor measurement phantom allowed scanning of the phantom in preclinical US, CT and MRI scanners compared with only limited preclinical scanning capability of Mark 1 and Mark 2 phantoms. For all imaging modalities, RECIST and WHO errors were reduced for UTHSCSA multimodality tumor measurement phantom (≤1.69 ± 0.33%) compared with both Mark 1 (≤ -7.56 ± 6.52%) and Mark 2 (≤ 5.66 ± 1.41%) phantoms. For the UTHSCSA multimodality tumor measurement phantom, measured tumor volumes were highly correlated with NIST traceable design volumes for US (R2 = 1.000, p < 0.0001), CT (R2 = 0.9999, p < 0.0001) and MRI (R2 = 0.9998, p < 0.0001).Conclusions: The UTHSCSA multimodality tumor measurement phantom described in this study can potentially be a useful quality assurance tool for verifying radiologic assessment of tumor size change during preclinical anti-cancer therapy testing with multiple imaging modalities.

Original languageEnglish (US)
Article number1
JournalBMC Medical Physics
Volume11
Issue number1
DOIs
StatePublished - Sep 30 2011

Fingerprint

Neoplasms
Tomography
Magnetic Resonance Imaging
X-Ray Computed Tomography Scanners
United States Food and Drug Administration
Tumor Biomarkers
Tumor Burden
Pharmaceutical Preparations
Ultrasonography
Drug Therapy
Equipment and Supplies
Response Evaluation Criteria in Solid Tumors

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Lee, Y. C., Fullerton, G. D., Baiu, C., Lescrenier, M. G., & Goins, B. A. (2011). Preclinical multimodality phantom design for quality assurance of tumor size measurement. BMC Medical Physics, 11(1), [1]. https://doi.org/10.1186/1756-6649-11-1

Preclinical multimodality phantom design for quality assurance of tumor size measurement. / Lee, Yongsook C.; Fullerton, Gary D.; Baiu, Cristel; Lescrenier, Margaret G.; Goins, Beth A.

In: BMC Medical Physics, Vol. 11, No. 1, 1, 30.09.2011.

Research output: Contribution to journalArticle

Lee, Yongsook C. ; Fullerton, Gary D. ; Baiu, Cristel ; Lescrenier, Margaret G. ; Goins, Beth A. / Preclinical multimodality phantom design for quality assurance of tumor size measurement. In: BMC Medical Physics. 2011 ; Vol. 11, No. 1.
@article{6758eaea4f574f6384f6884707c5defa,
title = "Preclinical multimodality phantom design for quality assurance of tumor size measurement",
abstract = "Background: Evaluation of changes in tumor size from images acquired by ultrasound (US), computed tomography (CT) or magnetic resonance imaging (MRI) is a common measure of cancer chemotherapy efficacy. Tumor size measurement based on either the World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST) is the only imaging biomarker for anti-cancer drug testing presently approved by the United States Food and Drug Administration (FDA). The aim of this paper was to design and test a quality assurance phantom with the capability of monitoring tumor size changes with multiple preclinical imaging scanners (US, CT and MRI) in order to facilitate preclinical anti-cancer drug testing.Methods: Three phantoms (Gammex/UTHSCSA Mark 1, Gammex/UTHSCSA Mark 2 and UTHSCSA multimodality tumor measurement phantom) containing tumor-simulating test objects were designed and constructed. All three phantoms were scanned in US, CT and MRI devices. The size of test objects in the phantoms was measured from the US, CT and MRI images. RECIST, WHO and volume analyses were performed.Results: The smaller phantom size, simplified design and better test object CT contrast of the UTHSCSA multimodality tumor measurement phantom allowed scanning of the phantom in preclinical US, CT and MRI scanners compared with only limited preclinical scanning capability of Mark 1 and Mark 2 phantoms. For all imaging modalities, RECIST and WHO errors were reduced for UTHSCSA multimodality tumor measurement phantom (≤1.69 ± 0.33{\%}) compared with both Mark 1 (≤ -7.56 ± 6.52{\%}) and Mark 2 (≤ 5.66 ± 1.41{\%}) phantoms. For the UTHSCSA multimodality tumor measurement phantom, measured tumor volumes were highly correlated with NIST traceable design volumes for US (R2 = 1.000, p < 0.0001), CT (R2 = 0.9999, p < 0.0001) and MRI (R2 = 0.9998, p < 0.0001).Conclusions: The UTHSCSA multimodality tumor measurement phantom described in this study can potentially be a useful quality assurance tool for verifying radiologic assessment of tumor size change during preclinical anti-cancer therapy testing with multiple imaging modalities.",
author = "Lee, {Yongsook C.} and Fullerton, {Gary D.} and Cristel Baiu and Lescrenier, {Margaret G.} and Goins, {Beth A.}",
year = "2011",
month = "9",
day = "30",
doi = "10.1186/1756-6649-11-1",
language = "English (US)",
volume = "11",
journal = "BMC Nuclear Medicine",
issn = "1756-6649",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Preclinical multimodality phantom design for quality assurance of tumor size measurement

AU - Lee, Yongsook C.

AU - Fullerton, Gary D.

AU - Baiu, Cristel

AU - Lescrenier, Margaret G.

AU - Goins, Beth A.

PY - 2011/9/30

Y1 - 2011/9/30

N2 - Background: Evaluation of changes in tumor size from images acquired by ultrasound (US), computed tomography (CT) or magnetic resonance imaging (MRI) is a common measure of cancer chemotherapy efficacy. Tumor size measurement based on either the World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST) is the only imaging biomarker for anti-cancer drug testing presently approved by the United States Food and Drug Administration (FDA). The aim of this paper was to design and test a quality assurance phantom with the capability of monitoring tumor size changes with multiple preclinical imaging scanners (US, CT and MRI) in order to facilitate preclinical anti-cancer drug testing.Methods: Three phantoms (Gammex/UTHSCSA Mark 1, Gammex/UTHSCSA Mark 2 and UTHSCSA multimodality tumor measurement phantom) containing tumor-simulating test objects were designed and constructed. All three phantoms were scanned in US, CT and MRI devices. The size of test objects in the phantoms was measured from the US, CT and MRI images. RECIST, WHO and volume analyses were performed.Results: The smaller phantom size, simplified design and better test object CT contrast of the UTHSCSA multimodality tumor measurement phantom allowed scanning of the phantom in preclinical US, CT and MRI scanners compared with only limited preclinical scanning capability of Mark 1 and Mark 2 phantoms. For all imaging modalities, RECIST and WHO errors were reduced for UTHSCSA multimodality tumor measurement phantom (≤1.69 ± 0.33%) compared with both Mark 1 (≤ -7.56 ± 6.52%) and Mark 2 (≤ 5.66 ± 1.41%) phantoms. For the UTHSCSA multimodality tumor measurement phantom, measured tumor volumes were highly correlated with NIST traceable design volumes for US (R2 = 1.000, p < 0.0001), CT (R2 = 0.9999, p < 0.0001) and MRI (R2 = 0.9998, p < 0.0001).Conclusions: The UTHSCSA multimodality tumor measurement phantom described in this study can potentially be a useful quality assurance tool for verifying radiologic assessment of tumor size change during preclinical anti-cancer therapy testing with multiple imaging modalities.

AB - Background: Evaluation of changes in tumor size from images acquired by ultrasound (US), computed tomography (CT) or magnetic resonance imaging (MRI) is a common measure of cancer chemotherapy efficacy. Tumor size measurement based on either the World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST) is the only imaging biomarker for anti-cancer drug testing presently approved by the United States Food and Drug Administration (FDA). The aim of this paper was to design and test a quality assurance phantom with the capability of monitoring tumor size changes with multiple preclinical imaging scanners (US, CT and MRI) in order to facilitate preclinical anti-cancer drug testing.Methods: Three phantoms (Gammex/UTHSCSA Mark 1, Gammex/UTHSCSA Mark 2 and UTHSCSA multimodality tumor measurement phantom) containing tumor-simulating test objects were designed and constructed. All three phantoms were scanned in US, CT and MRI devices. The size of test objects in the phantoms was measured from the US, CT and MRI images. RECIST, WHO and volume analyses were performed.Results: The smaller phantom size, simplified design and better test object CT contrast of the UTHSCSA multimodality tumor measurement phantom allowed scanning of the phantom in preclinical US, CT and MRI scanners compared with only limited preclinical scanning capability of Mark 1 and Mark 2 phantoms. For all imaging modalities, RECIST and WHO errors were reduced for UTHSCSA multimodality tumor measurement phantom (≤1.69 ± 0.33%) compared with both Mark 1 (≤ -7.56 ± 6.52%) and Mark 2 (≤ 5.66 ± 1.41%) phantoms. For the UTHSCSA multimodality tumor measurement phantom, measured tumor volumes were highly correlated with NIST traceable design volumes for US (R2 = 1.000, p < 0.0001), CT (R2 = 0.9999, p < 0.0001) and MRI (R2 = 0.9998, p < 0.0001).Conclusions: The UTHSCSA multimodality tumor measurement phantom described in this study can potentially be a useful quality assurance tool for verifying radiologic assessment of tumor size change during preclinical anti-cancer therapy testing with multiple imaging modalities.

UR - http://www.scopus.com/inward/record.url?scp=80053357741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053357741&partnerID=8YFLogxK

U2 - 10.1186/1756-6649-11-1

DO - 10.1186/1756-6649-11-1

M3 - Article

C2 - 21958653

AN - SCOPUS:80053357741

VL - 11

JO - BMC Nuclear Medicine

JF - BMC Nuclear Medicine

SN - 1756-6649

IS - 1

M1 - 1

ER -